# Phase 2A Extended: Hypothesis Clarification

**Date:** 2026-02-06
**Author:** Pray
**Source Round:** 02a_round_1_discussion.md
**Status:** Ready for Phase 2B Verification Planning

---

## 1. Clarified Hypothesis

### 1.1 Core Statement

**Hypothesis ID:** H-GenAI-ViL-v1
**Confidence Level:** 0.82

**Main Hypothesis:**
Under the condition of generative medical AI model validation, if a three-stage Validation-in-the-Loop (ViL) framework is implemented (Data-in-Loop automated screening → Clinician-in-Loop stratified sampling → Deployment-in-Loop continuous monitoring), then validation costs will significantly decrease while maintaining clinical safety (False Negative Rate <5%), because automated pre-screening filters models before expensive expert evaluation, stratified sampling targets high-risk cases efficiently, and continuous monitoring detects performance drift early.

**Alternative Hypothesis (H0):**
There is no significant difference in validation costs or clinical safety between the GenAI-ViL three-stage framework and traditional ad-hoc validation approaches. The proposed staged validation does not reduce expert time or maintain equivalent safety standards.

### 1.2 Variables

| Variable | Type | Operationalization | Expected Range/Values |
|----------|------|-------------------|----------------------|
| Loop 1 Metric Thresholds | Independent | FID, SSIM, Hellinger distance cutoff values for automated pass/fail decisions | FID <50, SSIM >0.7, Hellinger <0.3 |
| Loop 2 Sampling Strategy | Independent | Stratified sampling protocol: (a) threshold boundaries, (b) contradictory metrics, (c) random passing cases, (d) all failing cases | Sampling ratio 20-40% of passing models |
| Loop 3 Monitoring Protocol | Independent | Federated learning-compatible drift detection with re-evaluation triggers | Drift threshold: performance drop >10% |
| Validation Cost | Dependent | Total time and financial resources (expert hours × cost + compute cost) | Target: 40-60% reduction vs baseline |
| Expert Validation Time | Dependent | Clinical expert hours required for validation assessment | Target: <40 hours per model (vs ~100 hours baseline) |
| False Negative Rate | Dependent | Proportion of unsafe models incorrectly passing validation | Target: <5% (safety threshold) |
| Regulatory Approval Rate | Dependent | Proportion of validated models achieving FDA approval | Target: ≥70% approval rate |
| Generative Model Type | Controlled | GAN, Diffusion, VAE, Normalizing Flow architectures | All major architectures tested |
| Medical Imaging Modality | Controlled | CT, MRI, X-ray, PET scan types | Focus on CT and MRI (80% of use cases) |

### 1.3 Causal Mechanism

**Four-Stage Validation Efficiency Cascade (N=4):**

**Step 1: Automated Filtering → Filtered Model Set**
Automated Loop 1 screening applies technical metrics (FID, SSIM, Hellinger distance, biomarker preservation) to eliminate clearly inadequate models. Only models passing ALL automated gates (estimated 30-50% of candidates) advance to Loop 2. This creates a filtered model set with higher expected clinical utility.

**Step 2: Filtered Model Set → Reduced Expert Workload**
Because only models passing automated gates reach Loop 2, the total number of models requiring expert review decreases by 50-70%. This filtered set directly reduces expert workload measured in total clinical hours required for validation.

**Step 3: Stratified Sampling Protocol → High-Efficiency Expert Validation**
Within the filtered set, stratified sampling targets: (a) cases near threshold boundaries (highest information value), (b) cases with contradictory metrics (error detection), (c) random samples from passing cases (coverage verification), (d) all failing cases (error analysis). This protocol maximizes information gain per expert hour, achieving 80-95% validation accuracy with only 20-40% sampling coverage.

**Step 4: Continuous Loop 3 Monitoring → Early Drift Detection**
Post-deployment, federated learning across multiple sites enables continuous performance monitoring. When performance degrades >10% at any site, automated alerts trigger re-evaluation BEFORE clinical harm occurs. Early detection prevents catastrophic failures and maintains long-term safety.

**Evidence for Causal Links:**

| Link | Evidence Source | Key Finding | Strength |
|------|-----------------|-------------|----------|
| Step 1 → Step 2 | El Emam 2022 (Scholar); SMD_ScoreCard, syntheval (Exa) | Hellinger distance validated for synthetic data ranking; automated tools demonstrate feasibility | Medium (technical validation exists but not medical-specific) |
| Step 2 → Step 3 | Grau 2024 (Scholar - XiL for medical devices) | Staged validation in Systems Engineering reduces downstream effort by 60-80% through automated pre-screening | Strong (cross-domain transfer from proven methodology) |
| Step 3 → Step 4 | Silva 2025 (Scholar - doctor-in-loop); ML sampling theory | Structured expert assessment with stratified sampling improves efficiency; sampling theory supports information maximization | Medium (methodology exists but medical AI validation context unvalidated) |
| Step 4 → Outcome | AHA 2025 advisory (Scholar); Grover 2025 (Scholar - continuous QA); SynthRAD2023 (Scholar) | 3-phase framework with postdeployment monitoring proposed; continuous QA in ML demonstrates drift detection; multi-center feasibility shown | Strong (advisory recommendation + technical feasibility proven) |

**Key Tension:**
**Tension:** Grau 2024 Systems Engineering X-in-the-Loop shows 60-80% efficiency gains for medical DEVICES with deterministic behavior, but generative AI models exhibit stochastic outputs and distribution shifts. The Phase 2A Skeptic identified this as "analogy validity: PARTIALLY VALID" because devices ≠ AI.

**Resolution:** Phase 0 pilot study will empirically validate the automated-to-clinical metric correlation (automated metrics → clinical utility link). If correlation ≥0.7, the efficiency cascade holds despite stochasticity. If <0.7, the framework requires threshold recalibration or additional validation dimensions. This tension is the CRITICAL assumption requiring empirical validation before full deployment.

### 1.4 Key Assumptions

1. **Automated technical metrics (FID, SSIM, Hellinger distance, biomarker preservation) correlate with clinical utility (correlation ≥0.7)**
   - Supporting Evidence: El Emam 2022 validated Hellinger distance for synthetic data utility ranking across 30 health datasets
   - **Consequence if Violated**: If correlation <0.7, false negatives increase (unsafe models pass Loop 1), cascading into unacceptable False Negative Rate >5%. Entire framework collapses. REQUIRES Phase 0 pilot validation.

2. **Stratified sampling maintains ≥95% validation accuracy while reviewing only 20-40% of passing models**
   - Supporting Evidence: General ML sampling theory; Silva 2025 doctor-in-loop methodology demonstrates structured expert assessment
   - **Consequence if Violated**: If accuracy <95% or required coverage >80%, efficiency gains vanish. Expert time not reduced sufficiently to justify framework overhead.

3. **FDA will accept three-stage validation as regulatory-grade evidence for approval decisions**
   - Supporting Evidence: AHA 2025 advisory proposes 3-phase framework (predeployment, implementation, postdeployment) but no official FDA endorsement yet
   - **Consequence if Violated**: If FDA rejects framework, validated models cannot achieve regulatory approval despite passing all ViL stages. Framework becomes non-viable for clinical deployment.

4. **Existing tools (SMD_ScoreCard, syntheval, synthEHRella) can be integrated into Loop 1 automated pipeline with <20% engineering overhead**
   - Supporting Evidence: Tools exist as open-source Python libraries with documented APIs (from Exa Phase 1 search)
   - **Consequence if Violated**: If integration requires >50% overhead or tools incompatible, Loop 1 automation costs exceed savings from reduced expert time.

5. **Multi-center deployment via federated learning maintains privacy while enabling performance monitoring across ≥3 sites**
   - Supporting Evidence: SynthRAD2023 demonstrated multi-center validation feasibility (540 brain + 540 pelvis scans across 3 centers with varying protocols)
   - **Consequence if Violated**: If federated learning introduces >1% patient re-identification risk or monitoring lag >6 months, Loop 3 becomes non-viable due to privacy/safety concerns.

### 1.5 Scope & Boundaries

**Where Hypothesis Applies:**
- Generative medical AI models for medical imaging synthesis (CT, MRI, X-ray, PET)
- Synthetic medical data generation for training/augmentation purposes
- Healthcare institutions with access to clinical experts (radiologists, pathologists)
- Contexts where validation cost is a significant barrier to deployment (resource-constrained settings, rapid iteration environments)
- Regulatory environments requiring FDA approval or equivalent (US, EU medical device regulations)

**Where It Does NOT Apply:**
- Non-generative AI models (discriminative models for classification/segmentation) - different validation requirements
- Non-medical AI domains - clinical safety requirements are domain-specific
- Real-time emergency applications requiring <1 hour validation - framework requires days-weeks for complete validation cycle
- Solo practitioner settings without multi-expert access - stratified sampling requires multiple expert perspectives
- Non-imaging medical modalities (genomics, EHR text, time-series vitals) - automated metrics (FID, SSIM) are image-specific

**Known Limitations:**
1. Framework requires Phase 0 pilot (3-6 months) to validate automated-to-clinical correlation before deployment
2. Initial setup overhead (tool integration, threshold calibration) may require 6-12 months before efficiency gains realized
3. Cross-domain transfer from Systems Engineering X-in-the-Loop validated for devices but not AI - analogy strength: MEDIUM
4. Threshold values (FID <50, correlation ≥0.7, sampling 20-40%) are preliminary estimates requiring empirical tuning
5. Federated learning privacy-performance trade-off not yet optimized - may require differential privacy with utility degradation

### 1.6 Testable Predictions

**Primary Prediction:**
**P1 (Validation Cost Reduction - Absolute Performance Mode):**
The GenAI-ViL three-stage framework will achieve validation cost reduction >40% compared to traditional ad-hoc validation while maintaining False Negative Rate <5%.

*Measurement*:
- Validation Cost = (Expert Hours × $200/hour) + Compute Cost
- Target: >40% cost reduction with p < 0.05 (Cohen's d > 0.5)
- Statistical test: Paired comparison (same model set validated with both methods), n ≥ 20 models
- False Negative Rate measured via retrospective clinical outcome analysis at 6-month follow-up

*Basis*:
Domain standard for medical AI validation frameworks. 40% reduction represents meaningful improvement threshold for clinical adoption (based on AHA 2025 advisory resource constraint identification). False Negative Rate <5% is standard safety threshold in medical device validation.

*Success Criteria for Phase 2B*:
- Primary: Cost reduction >40% AND False Negative Rate <5% (both must hold)
- Minimum acceptable: Cost reduction >25% AND False Negative Rate <10% (triggers framework refinement)
- Falsification: Cost reduction <15% OR False Negative Rate >15% (triggers rejection)

**Secondary Predictions:**
**P2 (Expert Time Reduction - Mechanism Validation):**
Loop 1 automated filtering + Loop 2 stratified sampling will reduce expert validation time by >50% (from baseline ~100 hours to <40 hours per model).

*Measurement*: Expert hours logged per validation case, compared between traditional vs GenAI-ViL approach
*Basis*: Grau 2024 Systems Engineering X-in-the-Loop reports 60-80% efficiency gains; conservative 50% target accounts for AI vs device differences

**P3 (Regulatory Approval Rate - Practical Impact):**
Models validated through GenAI-ViL will achieve FDA approval rate ≥70%, demonstrating regulatory acceptance of the framework.

*Measurement*: Proportion of ViL-validated models achieving FDA 510(k) clearance or De Novo authorization within 12 months
*Basis*: Current medical AI FDA approval rates ~50-60%; ViL's regulatory-grade evidence trails should improve approval likelihood

**Falsification Criteria:**
The hypothesis will be **REJECTED** if any of the following occur:

1. **Primary Failure (Safety Violation)**: False Negative Rate >15%
   - Indicates automated filtering or stratified sampling misses critical unsafe models
   - Safety threshold breach makes framework clinically unacceptable regardless of cost savings

2. **Primary Failure (Insufficient Cost Reduction)**: Validation cost reduction <15%
   - Indicates framework overhead exceeds efficiency gains
   - Below minimum meaningful improvement for justifying adoption

3. **Mechanism Failure (Correlation Breakdown)**: Phase 0 pilot shows automated-to-clinical metric correlation <0.7
   - Core assumption violated - automated metrics don't predict clinical utility
   - Entire validation efficiency cascade collapses at Step 1

4. **Adoption Failure (Regulatory Rejection)**: FDA approval rate <50%
   - Indicates regulatory bodies don't accept ViL as valid evidence
   - Framework produces validation without regulatory value

5. **Baseline Failure (Worse Than Current)**: Validation costs INCREASE or safety DECREASES compared to ad-hoc validation
   - Framework actively harmful - current fragmented approach superior

### 1.7 SOTA Baseline (Optional - If SOTA Comparison Mode)

N/A - This is a framework validation study, not a performance comparison study. No SOTA performance benchmarks applicable. Comparison is against "traditional ad-hoc validation" baseline (current practice) rather than state-of-the-art methods.

### 1.8 Statistical Verification Design

**Sample Size Calculation (Absolute Performance Mode):**
- Minimum models: n ≥ 20 generative medical AI models (mixed architectures: GAN, Diffusion, VAE)
- Rationale: Sufficient for detecting >40% cost difference with statistical power 0.8, α = 0.05
- Model diversity: Include 10 CT synthesis models + 10 MRI synthesis models

**Validation Methodology:**
1. **Paired Comparison Design**: Same 20 models validated using BOTH methods:
   - Method A: Traditional ad-hoc validation (baseline)
   - Method B: GenAI-ViL three-stage framework
2. **Blinding**: Clinical experts blinded to validation method during Loop 2 assessment
3. **Outcome Measures**:
   - Primary: Total validation cost (dollars), False Negative Rate (proportion)
   - Secondary: Expert time (hours), regulatory approval rate (proportion)

**Statistical Tests:**
- **Cost Reduction**: Paired t-test (MethodA_cost - MethodB_cost), one-tailed, α = 0.05
  - Report: Mean difference, 95% CI, Cohen's d, p-value
  - Success: p < 0.05 AND mean reduction >40%
- **Safety**: McNemar's test for paired proportions (False Negative Rate comparison)
  - Report: Rate difference, 95% CI, p-value
  - Success: p > 0.05 (non-inferior) AND rate <5% (absolute threshold)

**Phase 0 Pilot Requirements (CRITICAL):**
Before full validation study, Phase 0 pilot must establish:
1. Automated-to-clinical metric correlation: Pearson r ≥ 0.7 (p < 0.01)
   - Method: 50 synthetic medical images rated by automated metrics + 3 clinical experts
   - Analysis: Correlation between automated scores and expert clinical utility ratings
2. Threshold Calibration: Determine optimal FID, SSIM, Hellinger cutoffs maximizing separation
3. Duration: 3-6 months

**Report Format:**
- Mean ± SD for all continuous metrics
- 95% Confidence Intervals for all effects
- Cohen's d for cost difference (effect size)
- P-values for all statistical tests
- Sensitivity analysis: Results stratified by model type (GAN vs Diffusion) and modality (CT vs MRI)

---

## 2. Contribution Summary

**Theoretical Contribution:**
Establishes formal connection between Systems Engineering Verification & Validation (V&V) methodology and clinical AI validation. Introduces the concept of "validation efficiency frontier" - the trade-off surface between expert time investment and validation accuracy. Defines staged gate validation theory for generative medical AI with explicit false positive/negative trade-offs, adapting X-in-the-Loop methodology (Grau 2024) from deterministic medical devices to stochastic AI systems.

**Methodological Contribution:**
1. **Novel Three-Stage Validation-in-the-Loop (ViL) Protocol**: First structured framework combining Data-in-Loop (automated screening) → Clinician-in-Loop (stratified sampling) → Deployment-in-Loop (federated monitoring) specifically designed for generative medical AI
2. **Automated Pre-Screening Methodology**: Integration of multiple technical + biomedical metrics (FID, SSIM, Hellinger distance, biomarker preservation) via existing tools (SMD_ScoreCard, syntheval, synthEHRella) into unified automated filtering system - reduces expert validation burden by filtering 50-70% of candidates pre-expert review
3. **Stratified Sampling Strategy for Clinical Validation**: Targeting (a) threshold boundaries, (b) contradictory metrics, (c) random passing cases, (d) all failing cases - maximizes information gain per expert hour, achieving 80-95% accuracy with 20-40% sampling coverage
4. **Federated Learning-Compatible Deployment Monitoring**: Privacy-preserving multi-center validation protocol enabling continuous performance monitoring across healthcare institutions without centralized patient data sharing

**Practical Contribution:**
1. **Cost Reduction**: Target 40-60% validation cost reduction through automation cascade - makes generative medical AI validation economically viable for resource-constrained healthcare settings
2. **Regulatory-Grade Evidence Trails**: Staged gate documentation (Loop 1 automated metrics → Loop 2 expert assessments → Loop 3 monitoring logs) provides audit-ready validation records addressing FDA approval bottleneck identified in Phase 1 research
3. **Standardized Cross-Institutional Validation**: Federated approach enables consistent validation methodology across healthcare institutions, addressing SynthRAD2023 multi-center challenge and fragmentation problem (Gap 2 from Phase 1)
4. **Adoption Incentive via Economic Benefits**: Unlike regulation-driven adoption (compliance-only), ViL creates economic incentive (cost savings) driving voluntary adoption beyond mandates - addresses key adoption barrier from Phase 2A Strategist analysis

**Differentiation from Existing Work:**
- **vs AHA 2025 Advisory (Jain et al.)**: AHA proposes 3-phase framework (predeployment, implementation, postdeployment) but lacks PRACTICAL IMPLEMENTATION PATHWAY. GenAI-ViL provides concrete operational protocol with tool integration, sampling strategies, and threshold specifications.
- **vs Udechukwu 2025 (governance framework)**: Focuses on governance and data privacy, not validation methodology. Complementary scope.
- **vs Fadul 2025 (review)**: Identifies gap (calls for standards) but proposes no solution. GenAI-ViL fills this gap.
- **vs Systems Engineering X-in-the-Loop (Grau 2024)**: First application of XiL to generative AI (not devices). Adapts for stochastic systems with Phase 0 pilot validation of correlation assumptions.

---

## 3. Key Related Work

| Source | Type | Key Insight | Role in Hypothesis |
|--------|------|-------------|-------------------|
| **Grau et al. 2024** - Medical Device Validation: X-In-The-Loop Framework | [SCHOLAR] Cross-Domain | Systems Engineering XiL provides systematic staged validation (Model-in-Loop → Software-in-Loop → Hardware-in-Loop) with proven 60-80% efficiency gains for medical devices in highly regulated markets | **Primary Inspiration**: Adapted XiL stages to GenAI-ViL loops. Provides theoretical foundation for staged validation efficiency cascade. Transferred gate validation concept with mixed automated/human checks. |
| **Jain et al. 2025** - AHA Advisory: AI Evaluation & Monitoring | [SCHOLAR] Medical AI | Proposes 3-phase framework (predeployment, implementation, postdeployment) for healthcare AI with risk-proportionate evaluation. Identifies resource constraints and need for pragmatic approaches. | **Loop 2 Structure**: GenAI-ViL Loop 2 (Clinician-in-Loop) adapts AHA 3-phase framework for structured expert clinical assessment. Addresses AHA's identified gap by providing practical implementation pathway. |
| **El Emam et al. 2022** - Utility Metrics for Synthetic Health Data | [SCHOLAR] Medical AI | Validated multivariate Hellinger distance as reliable metric to rank synthetic data generation methods across 30 health datasets. Provides empirical evidence for automated utility evaluation. | **Loop 1 Metrics**: Hellinger distance integrated into Loop 1 automated utility evaluation alongside FID/SSIM. Supports automated-to-clinical correlation assumption with empirical validation. |
| **Silva et al. 2025** - Doctor-in-the-Loop Qualitative Evaluation | [SCHOLAR] Medical AI | Methodology for efficient clinical expert evaluation of synthetic medical data through structured assessment protocols. Demonstrates feasibility of expert sampling approaches. | **Loop 2 Sampling**: Loop 2 stratified sampling incorporates Silva's doctor-in-loop methodology for structured expert assessment protocol. Provides evidence for expert efficiency gains. |
| **Thummerer et al. 2023** - SynthRAD2023 Grand Challenge | [SCHOLAR] Medical AI | Multi-center dataset (540 brain + 540 pelvis CT/CBCT/MRI) across 3 centers with varying protocols. Demonstrates feasibility of multi-institutional validation for synthetic medical data. | **Loop 3 Federated**: Provides empirical evidence that multi-center validation is technically feasible. SynthRAD2023 dataset can serve as validation benchmark for ViL framework testing. |
| **Grover et al. 2025** - Continuous QA for Adaptive ML Systems | [SCHOLAR] Software Engineering | Continuous verification in ML systems through automated QA pipelines embedded in MLOps. Demonstrates real-time quality assurance reduces model failures and shortens feedback-to-repair cycles. | **Loop 3 Monitoring**: Loop 3 continuous monitoring inspired by Software QA continuous verification pipelines. Provides technical precedent for automated post-deployment drift detection. |
| **SMD_ScoreCard** - Synthetic Medical Data Evaluation Library | [EXA] Implementation | Python library for evaluating quality of synthetic medical data with automated metrics. Open-source tool reducing implementation burden for automated validation. | **Loop 1 Integration**: Integrated into Loop 1 automated technical metric evaluation. Reduces engineering overhead for implementing automated filtering. |
| **synthEHRella** - Synthetic EHR Benchmarking Package | [EXA] Implementation | Benchmarking package for evaluating synthetic EHR data generation methods. Provides standardized evaluation protocols. | **Loop 1 Integration**: Integrated into Loop 1 automated evaluation pipeline for comprehensive benchmarking alongside SMD_ScoreCard. |
| **syntheval** - Synthetic Data Quality Evaluation | [EXA] Implementation | Software for evaluating quality of synthetic data vs real data. Provides comparative quality metrics. | **Loop 1 Integration**: Integrated into Loop 1 automated quality evaluation alongside SMD_ScoreCard and synthEHRella. Completes automated tool suite. |

**Evidence Gap Addressed:**
Phase 1 research identified Gap 2 (Lack of Standardized Clinical Validation Frameworks for Generative Medical AI) as CRITICAL priority. Existing frameworks (AHA 2025) proposed structure but lacked practical implementation. GenAI-ViL bridges this gap by providing:
1. Operational protocol with tool integration (addresses "how to implement")
2. Economic incentive for adoption (addresses "why adopt beyond compliance")
3. Empirical validation pathway via Phase 0 pilot (addresses "proof of effectiveness")

---

## 4. Phase 2B Readiness

### Decomposition Preview

**SH1 (Existence - Loop 1 Automated Filtering):**
Verify that automated technical metrics (FID, SSIM, Hellinger distance, biomarker preservation) can filter generative medical AI models with ≥70% automated-to-clinical correlation.

*Validation Experiment*: Phase 0 pilot study with 50 synthetic medical images evaluated by automated metrics + 3 clinical experts. Measure Pearson correlation between automated scores and expert clinical utility ratings. Success: r ≥ 0.7, p < 0.01.

**SH2 (Mechanism - Validation Efficiency Cascade):**
Verify that the four-stage causal mechanism (Automated Filtering → Reduced Workload → High-Efficiency Sampling → Early Drift Detection) operates as proposed, producing 40-60% cost reduction.

*Validation Experiment*: Paired comparison study with n ≥ 20 models validated via traditional vs ViL methods. Measure cost reduction, expert time, and False Negative Rate. Success: >40% cost reduction, <5% FNR, p < 0.05.

**SH3 (Comparison - vs Traditional Ad-Hoc Validation):**
Verify that GenAI-ViL framework produces superior cost-safety trade-off compared to traditional ad-hoc validation approaches currently used in practice.

*Validation Experiment*: Same as SH2 (paired comparison design enables direct comparison). Baseline: current practice validation costs and safety rates. Success: ViL significantly better on both dimensions (cost AND safety).

### Readiness Checklist

- [x] **Variables Operationalized**: All 9 variables have explicit measurement methods and expected ranges
- [x] **Causal Mechanism Decomposed**: Four-stage cascade with evidence and falsification conditions for each link
- [x] **Assumptions Identified**: Five core assumptions with supporting evidence and consequences if violated
- [x] **Testable Predictions Defined**: Primary + 2 secondary predictions with quantitative thresholds (>40% cost reduction, <5% FNR)
- [x] **Falsification Criteria Specified**: Five explicit rejection conditions with quantitative thresholds
- [x] **Statistical Design Documented**: Sample size (n ≥ 20), paired comparison methodology, statistical tests specified
- [x] **Evidence Base Established**: 9 key sources mapped to specific hypothesis components (4 Scholar, 0 Archon, 3 Exa, 2 Cross-Domain)
- [x] **Phase 0 Pilot Requirements**: Correlation validation study specified (3-6 months, 50 images, 3 experts, r ≥ 0.7 target)
- [x] **Sub-Hypothesis Preview**: SH1 (Existence), SH2 (Mechanism), SH3 (Comparison) clearly defined with distinct validation experiments
- [⚠️] **Open Questions Identified**: See below - 3 critical questions requiring Phase 2B investigation

**Overall Readiness: 90%** - Hypothesis is scientifically structured, quantitatively specified, and evidence-linked. Ready for Phase 2B verification planning pending resolution of open questions.

### Open Questions

1. **Threshold Optimization (CRITICAL for SH1):**
   - **Question**: What are the optimal Loop 1 threshold values (FID cutoff, SSIM cutoff, Hellinger cutoff, biomarker preservation threshold) that maximize automated-to-clinical correlation while maintaining acceptable false positive/negative rates?
   - **Impact**: Directly determines SH1 success. Phase 0 pilot must include threshold calibration experiments with ROC analysis.
   - **Resolution Path**: Phase 2B should decompose SH1 into threshold calibration sub-hypothesis with grid search validation experiment.

2. **Stratified Sampling Coverage Requirements (CRITICAL for SH2):**
   - **Question**: What is the minimum sampling coverage (% of passing models) required to achieve ≥95% validation accuracy using stratified sampling? Phase 2A assumed 20-40% but not empirically validated.
   - **Impact**: If coverage >80% required, efficiency gains vanish (SH2 mechanism failure). If coverage <10% sufficient, framework dramatically more efficient than estimated.
   - **Resolution Path**: Phase 2B should include sampling efficiency sub-hypothesis with coverage sensitivity analysis experiments.

3. **Federated Learning Privacy-Performance Trade-Off (MODERATE for SH2/SH3):**
   - **Question**: What level of differential privacy (epsilon value) is required in Loop 3 federated monitoring to maintain <1% re-identification risk, and how much does this degrade drift detection performance (monitoring lag, false alarm rate)?
   - **Impact**: Privacy constraints may necessitate monitoring protocol modifications. Trade-off optimization determines Loop 3 viability.
   - **Resolution Path**: Phase 2B should include federated privacy sub-hypothesis with epsilon sensitivity experiments simulating multi-site deployment.

---

*Generated using YouRA Research Phase 2A Extended Workflow (Focused)*
*Completed: 2026-02-06*
*YOLO MODE - Full Automation*
